The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

Disclosed herein are methods of producing aqueous dispersions comprising insoluble alpha-glucan having at least 50% alpha-1,3 glycosidic linkages. For example, in addition to dispersing insoluble alpha-glucan that has never been dried, methods are disclosed for effectively dispersing insoluble alpha-glucan that has previously been dried. Further disclosed are aqueous dispersions comprising insoluble alpha-glucan, such as those produced by the disclosed methods. Aqueous dispersions of the present disclosure have enhanced features of viscosity, stability, and particle size distribution, for example. Application of aqueous dispersions in various products and uses are also disclosed.

The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

This disclosure features compositions comprising niclosamide for use in treating one or more conditions (or one or more symptoms thereof) characterized by an abnormal inflammatory response in one or more particular subject (e.g., patient) populations in need thereof. Such conditions include, e.g., an autoimmune disorder, e.g., colitis, e.g., autoimmune colitis, e.g, an inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis. In some embodiments, the uses include rectally (e.g., via enema) administering niclosamide.

This disclosure features compositions comprising niclosamide for use in treating one or more conditions (or one or more symptoms thereof) characterized by an abnormal inflammatory response in one or more particular subject (e.g., patient) populations in need thereof. Such conditions include, e.g., an autoimmune disorder, e.g., colitis, e.g., autoimmune colitis, e.g, an inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis. In some embodiments, the uses include rectally (e.g., via enema) administering niclosamide.

The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.

A topical treatment for anorectal disorders with and without utilization of a contoured seat cushion with a temperature-adapted or electrical stimulation element that can provide hot or cold temperatures or electrical stimulation to the anorectal region.

The present invention relates to phosphate derivatives of formula (I), and their therapeutic uses, preferably for treating a respiratory disease. The present invention further relates to pharmaceutical compositions and devices comprising such compounds.